Home / Specialty Pharmacy

Specialty Pharmacy

Eisai Announces FDA Approval of Fycompa in Patients 4 Years and Older for Treatment of Partial-Onset Seizures

WOODCLIFF LAKE, N.J., Sept. 28, 2018 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized …

Read More »

Lilly’s Emgality Receives FDA Approval for the Prevention of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous injection.1 Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.1 …

Read More »

FDA Approves Teva’s Ajovy Injection for the Prevention and Treatment of Migraine in Adults

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the …

Read More »

Evolent Health to Expand its Specialty Care Management Capabilities through Acquisition of New Century Health

WASHINGTON, Sept. 12, 2018 /PRNewswire/ — Evolent Health, Inc. (NYSE : EVH ) – Evolent Health, Inc. (“Evolent”) and NCIS Holdings, Inc. and New Century Investment, LLC (“New Century Health”) announced today that they have entered into a definitive agreement for Evolent to acquire New Century Health’s business for up …

Read More »

FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain

SAN FRANCISCO–(BUSINESS WIRE)–Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for CA-008 in post-surgical pain. CA-008 is a first-in-class non-opioid therapeutic that rapidly converts to …

Read More »

Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and …

Read More »

Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Key Driver of Alzheimer’s Disease

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the discovery of an endogenous substance in human brain that inhibits the formation of neurotoxic beta amyloid (Aβ) oligomers, which are key drivers of AD …

Read More »

Newly Characterized Molecule Offers Possibilities for Novel Alzheimer’s Treatments

Alzheimer’s disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered its main biological features: amyloid-beta plaques and tau tangles. A study by researchers from Brigham and Women’s Hospital (BWH), recently published in Acta …

Read More »

Salix Collaborates with Cedars-Sinai Medical Center to Investigate Microbiome for Treatment of GI Disorders

BRIDGEWATER, N.J., Aug. 3, 2018 /PRNewswire/ — Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced its affiliate has entered into a research agreement with Cedars-Sinai Medical Center …

Read More »

FDA Approves Indivior’s Perseris for Extended-Release Injectable Suspension for the Treatment of Schizophrenia

Slough, UK and Richmond, VA, 30 July 2018 – Indivior PLC (LON: INDV) today announces that on July 27, 2018 the U.S. Food and Drug Administration (FDA) approved PERSERISTM, the first once-monthly subcutaneous risperidone-containing, long-acting injectable (LAI) for the treatment of schizophrenia in adults. Clinically relevant levels were reached after the first injection of PERSERIS …

Read More »